Atrial Septal Defect
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
atHeart MedicalSeptal defect closure
AbbottAMPLATZER Septal Occluder
Clinical Trials (2)
Total enrollment: 1,006 patients across 2 trials
Post Market Registry of the CBSO
Start: Mar 2020Est. completion: Oct 20246 patients
N/AUnknown
Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder - Post Approval Study
Start: Aug 2007Est. completion: Jun 20141,000 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.